TABLE 1 .
Sample | Strain | Passage history | Site 151 genotype |
Ct value |
---|---|---|---|---|
WSPHL1 | A/Washington/10/2013 | C1/C1 | X | 23.19 |
WSPHL2 | A/Washington/13/2013 | C1 | X | 17 |
WSPHL3 | A/Washington/17/2013 | C2 | X | 24.57 |
WSPHL4 | A/Washington/18/2013 | C3 | X | 21.52 |
WSPHL5 | A/Washington/08/2014 | C1 | X | 22.8 |
WSPHL6 | A/Washington/07/2015 | S3 | X | 23.78 |
WSPHL7 | A/Washington/24/2015 | S3 | X | 17.4 |
WSPHL8 | A/Washington/32/2015 | S3 | X | 18.69 |
WSPHL9 | A/Washington/36/2015 | S3 | X | 25.03 |
Genotypes were determined by Sanger sequencing of passaged isolates and are taken from those reported in the GISAID EpiFlu database. Annotations of passage history are not standardized, but Cn generally refers to n passages of the virus in cell culture prior to sequencing and Sn generally refers to n passages of the virus in MDCK-SIAT1 cells (17). For the genotype at site 151, an annotation of X indicates a mixture of D151 and G151 in the original Sanger sequencing. The Ct value is the amount of viral material in the original clinical sample as determined by quantitative PCR.